• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by RenovoRx Inc.

    2/14/22 6:33:04 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. __)*

     

     

    RENOVORX, INC.

    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    75989R 107

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 75989R 107

     

    1  

    NAME OF REPORTING PERSON:

     

    Kamran Najmabadi

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY:

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    70,000

    6

    SHARED VOTING POWER

     

    975,000

    7

    SOLE DISPOSITIVE POWER

     

    70,000

    8

    SHARED DISPOSITIVE POWER

     

    975,000

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     1,045,000(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    11.7%(2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

    (1) Includes (i) 10,000 shares of common stock held of record by Kamran Najmabadi (the “Reporting Person”); (ii) 60,000 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2021 to the Reporting Person; (iii) 731,250 shares of common stock held of record by The Najmabadi Family Trust dated April 22, 2021 for which the Reporting Person serves as a trustee; (iv) 121,875 shares of common stock held of record by The Navid Najmabadi Irrevocable Trust dated April 22, 2021 for which the Reporting Person serves as a trustee; and (v) 121,875 shares of common stock held of record by The Leili Najmabadi Irrevocable Trust dated April 22, 2021 for which the Reporting Person serves as a trustee.

     

    (2) Based on 8,908,150 shares of the Issuer’s common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 15, 2021.

     

     
     

     

    CUSIP No. 75989R 107   Page 3

     

    1  

    NAME OF REPORTING PERSON:

     

    The Najmabadi Family Trust dated April 22, 2021

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY:

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    California

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    731,250

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    731,250

    8

    SHARED DISPOSITIVE POWER

     

    0

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    731,250 (1)

    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    8.2% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    OO

     

    (1) The shares are held of record by The Najmabadi Family Trust dated April 22, 2021 for which Mr. Najmabadi serves as trustee.

     

    (2) Based on 8,908,150 shares of the Issuer’s common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 15, 2021.

     

     
     

     

    Item 1

     

    (a) Name of Issuer:

     

    RenovoRx, Inc.

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    4546 El Camino Real, Suite B1

    Los Altos, California 94022

     

    Item 2

     

    (a) Names of Persons Filing:

     

    Each of the following is a reporting person (“Reporting Person”):

     

    Kamran Najmabadi

    The Najmabadi Family Trust dated April 22, 2021

     

    (b) Address or principal business office or, if none, residence:

     

    The address for the principal business office of the Reporting Persons is:

     

    c/o RenovoRx, Inc.

    4546 El Camino Real, Suite B1

    Los Altos, California 94022

     

    (c) Citizenship:

     

    Reference is made to the response to item 4 on each of pages 2 and 3 of this Schedule 13G (this “Schedule”), which responses are incorporated herein by reference.

     

    (d) Title and Class of Securities:

     

    Common Stock, par value $0.0001 per share.

     

    (e) CUSIP No.:

     

    75989R 107

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership

     

    Reference is hereby made to the responses to items 5-9 and 11 of pages 2 and 3 of this Schedule, which responses are incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certifications

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2022    
         
        /s/ Kamran Najmabadi
        Kamran Najmabadi

     

      THE NAJMABADI FAMILY TRUST DATED APRIL 22, 2021
         
      By: /s/ Kamran Najmabadi
      Name: Kamran Najmabadi
      Title: Trustee

     

     

     

     

     

    Get the next $RNXT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

      Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.

      5/6/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

      Johns Hopkins Medicine's Valerie Lee, MD joins Michael J. Pishvaian, MD in an Appointed Key Role for TIGeR-PaC Trial By becoming an additional clinical site for TIGeR-PaC, Johns Hopkins Medicine joins several esteemed cancer centers to support RenovoRx's initiative to complete patient enrollment for the trial during 2025 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx's ongoing Phase III TIGeR

      4/29/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marton Laurence exercised 20,480 shares at a strike of $0.15, increasing direct ownership by 45% to 66,164 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      5/6/25 4:10:20 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Bagai Shaun

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 5:18:21 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Financials

    Live finance-specific insights

    See more
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    See more
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Closes $6.1 Million Private Placement

      With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

      1/29/24 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

      11/16/23 8:35:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on RenovoRx with a new price target

      Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

      11/1/21 11:49:10 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on RenovoRx with a new price target

      Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

      10/6/21 8:24:28 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

      SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

      2/14/23 4:51:34 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      4/14/22 2:24:24 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      2/14/22 6:33:04 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 6:08:22 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 2% to 1,098,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/14/25 6:30:30 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by RenovoRx Inc.

      SCHEDULE 13G - RenovoRx, Inc. (0001574094) (Subject)

      5/8/25 7:44:41 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by RenovoRx Inc.

      SCHEDULE 13G - RenovoRx, Inc. (0001574094) (Subject)

      5/7/25 4:34:20 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by RenovoRx Inc.

      DEF 14A - RenovoRx, Inc. (0001574094) (Filer)

      4/30/25 5:13:07 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care